Last reviewed · How we verify
cytarabine and mitoxantrone
Cytarabine is a nucleoside analog that interferes with DNA synthesis, while mitoxantrone is a topoisomerase II inhibitor that disrupts DNA replication and transcription.
Cytarabine is a nucleoside analog that interferes with DNA synthesis, while mitoxantrone is a topoisomerase II inhibitor that disrupts DNA replication and transcription. Used for Acute myeloid leukemia.
At a glance
| Generic name | cytarabine and mitoxantrone |
|---|---|
| Sponsor | Pfizer |
| Drug class | Antineoplastic agents |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cytarabine works by incorporating itself into DNA, causing strand breaks and inhibiting DNA synthesis. Mitoxantrone, on the other hand, intercalates DNA and inhibits topoisomerase II, leading to DNA damage and apoptosis. This combination of mechanisms makes cytarabine and mitoxantrone effective against rapidly dividing cancer cells.
Approved indications
- Acute myeloid leukemia
Common side effects
- Myelosuppression
- Nausea and vomiting
- Fatigue
- Infection
- Cardiac toxicity
Key clinical trials
- Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML (NA)
- Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML (PHASE3)
- A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML (PHASE2)
- IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. (PHASE3)
- CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia (PHASE1)
- Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma (PHASE3)
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cytarabine and mitoxantrone CI brief — competitive landscape report
- cytarabine and mitoxantrone updates RSS · CI watch RSS
- Pfizer portfolio CI